MetaVia reports Q1 net loss $3.7M; DA-1726 shows 4.3% mean weight loss in Phase 1

MetaVia Inc.

2025-Q1 EPS reported -$0.36

Cash $11.2M at Q1-end; plus $10M private placement in May, funding into 2026.
Net loss $3.7M ($0.36/sh) vs $6.7M ($1.32/sh) YoY; R&D spend down to $2.3M from $4.9M.
DA-1726 (obesity) mean weight loss 4.3% at 32 mg at Day 26 (p=0.0005); max 6.3%; no titration needed.
DA-1241 (MASH) Phase 2a reduced ALT 22.8 U/L at 16 weeks; end-of-Phase 2 FDA meeting expected H1 2025.
Additional DA-1726 dose cohorts to start Q3 2025; data expected Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.